Recent Oncology Drug Discovery Patent Applications

Highlights of recent US patent applications on cancer drug discovery.

1. Anti-VCAM1-tTF coaguligand for treating cancer
2. MicroRNA (miRNA) as therapeutic drugs for treating cancer
3. Anti-phoshatidylserine antibody-docetaxel combination therapy for the treatment of cancer
4. Targeted cancer therapy using miR-21 promoter driven expression of anti-cancer agents
5. miRNA-184 as therapeutic drug for treating squamous cell carcinoma
6. Protein kinase CK2 inhibitors for the treatment of cancer
7. Macrophage-stimulating protein receptor (MSP-R or RON) as a drug target for the treatment of cancer
8. Anti-K63-linked polyubiquitin monoclonal antibodies for the treatment of cancer, muscular, immune/inflammatory and neurological disorders
9. Oligonucleotide based drugs for the treatment of B-cell leukemias
10. Next-generation photosensitive medical agent that can simultaneously diagnose cancer and carry out photodynamic therapy (PDT)
11. Combination therapy for melanoma
12. MicroRNAs as therapeutic drugs for the treatment of sarcoma
13. Dual targeting antibodies of VEGFR-2 and Tie-2 receptors for treating cancer
14. A novel chlorin e6-folic acid conjugate for photodynamic therapy of malignant and solid tumors
15. Autotaxin inhibitors for the treatment of cancer

Details: http://www.sciclips.com/sciclips/drug-discovery-news.do"> http://www.sciclips.com/sciclips/drug-discovery-news.do

Recent patents on potential next generation sequencing diagnostics targets for schizophrenia, OHO tumors, and ADHR

Highlights of recent US patent applications

1. Glyoxalase I gene point mutation as a potential next generation sequencing diagnostics target of schizophrenia
2. FGF23 mRNA detection- a potential next generation sequencing diagnostics target of oncogenic hypophosphatemic osteomalacia (OHO) tumors
3. FGF23 missense mutations- potential next generation sequencing diagnostics target of autosomal dominant hypophosphatemic rickets (ADHR)

Details: http://www.sciclips.com/sciclips/biomarker-news.do

Recent patents on rheumatoid arthritis, cancer and schizophrenia theranostics

Highlights of recent US patent applications

1. Externalized phoshatidylserine as a global tumor blood vessel biomarker and a cancer theranostics target
   
2. PDE10 inhibitors for schizophrenia theranostics
3. Antibodies that specifically inhibit VEGF binding to VEGFR2 receptors for cancer theranostics
4. Radiolabeled cyclic pentapeptide drug for the diagnosis and treatment (theranostics) of cancer
5. T cells expressing B-Raf and K-Ras for rheumatoid arthritis theranostics (diagnostic therapy)
6. Phosphodiesterase 4D7 (PDE4D7) for prostate cancer theransotics (diagnostics therapy)
7. Phosphodiesterase 9A (PDE9A) for prostate cancer theransotics (diagnostics therapy)

Details: http://www.sciclips.com/sciclips/biomarker-news.do